Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01194427 · ClinicalTrials.gov registry record · Phase 2
A Study of Vorinostat and Tamoxifen in Newly Diagnosed Breast Cancer
A Phase 2 study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Terminated
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT01194427 is a Phase 2 study that was terminated before completion, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 2 participants.
The verdict
NCT01194427, a Phase 2 study, was terminated before completion, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
This research study is designed to look at the effects of the combination of vorinostat (Suberoylanilide Hydroxamic Acid or Zolinza) and tamoxifen on breast cancer tissue. The investigators will do this by comparing tissues from the original breast biopsy to tissues obtained after taking vorinostat and tamoxifen for 2 weeks.
Interventions
- DRUG Vorinostat and Tamoxifen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2011-03 |
| Est. Completion | 2011-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01194427
The ClinicalTrials.gov registry entry for NCT01194427 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Vorinostat and Tamoxifen is the first listed.
NCT01194427 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01194427 about?
NCT01194427 is a clinical study titled "A Study of Vorinostat and Tamoxifen in Newly Diagnosed Breast Cancer". This research study is designed to look at the effects of the combination of vorinostat (Suberoylanilide Hydroxamic Acid or Zolinza) and tamoxifen on breast cancer tissue. The investigators will do this by comparing tissues from the original breast biopsy to tissues obtained after taking vorinostat ...
What is the current status of trial NCT01194427?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2011-03. Estimated completion is 2011-11.
What interventions are being tested in trial NCT01194427?
The interventions under investigation include: Vorinostat and Tamoxifen (DRUG).
Who is sponsoring clinical trial NCT01194427?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.